A low-impairment AMPA receptor potentiator advanced through Phase 2 in treatment-resistant depression by Takeda and Neurocrine, distinguished from earlier ampakines by minimal receptor desensitization.
Abstract
TAK-653 (also designated NBI-1065845; emraclidine has the same NBI prefix, distinct compound; CAS 1626387-80-1; molecular formula C19H21F3N4O3S; molecular weight 442.46) is a small-molecule non-desensitizing positive allosteric modulator of AMPA-class glutamate receptors developed by Takeda and out-licensed to Neurocrine Biosciences for clinical development in treatment-resistant depression. The compound was selected from a structural class designed to achieve allosteric AMPA potentiation without the receptor desensitization characteristic of earlier ampakines (CX-516, CX-546), which limited potency and produced cognitive impairment at higher doses. TAK-653 binds at an allosteric site distinct from the glutamate-binding domain, slowing AMPA receptor deactivation and increasing the integrated current produced by physiological glutamate transients without persistent receptor activation in the absence of glutamate; this profile produces synaptic potentiation under physiological signaling without the off-target excitotoxicity concerns of full agonists or strongly desensitizing modulators. Phase 1 imaging studies report dose-dependent BOLD signal modulation in cortical regions consistent with AMPA potentiation. The compound was advanced through Phase 2 in treatment-resistant depression by Neurocrine; published Phase 2a results from 2023 reported numerical separation from placebo on Hamilton Depression Rating Scale change at week 4 with improvement maintained through week 8, with a favorable safety profile (no seizures, no notable sedation, no dose-limiting cognitive impairment). The compound has not yet received regulatory approval as of the most recent monograph revision. Distinguishing features versus other AMPA modulators are the absence of receptor desensitization, the minimal impairment profile at antidepressant doses, and the rapid-onset depression treatment positioning targeting the same therapeutic niche as ketamine and esketamine.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Benzocaine is the simplest ester local anesthetic, structurally just ethyl 4-aminobenzoate without the diethylamino-ethanol group of procaine. The simpler structure makes it lipophilic and poorly water-soluble, useful only for topical mucous membrane anesthesia. You know it as the active ingredient in Cepacol throat lozenges, Anbesol and Orajel oral gels, hemorrhoidal preparations, and topical ENT and bronchoscopy sprays. Onset is rapid (15 to 60 seconds on mucous membranes); duration is 5 to 15 minutes. The main safety concern is dose-dependent methemoglobinemia, more pronounced than with prilocaine, that has driven FDA boxed warnings against benzocaine spray and gel use in infants. The mechanism is hepatic conversion to nitroso and N-hydroxy metabolites that oxidize hemoglobin. The FDA advised against benzocaine teething gels in infants under two years in 2018. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Ester local anesthetic (topical only)
The simplest ester local anesthetic, used as a topical mucous membrane anesthetic and the principal ingredient in over-the-counter sore-throat lozenges.
Abstract
Benzocaine (ethyl 4-aminobenzoate; CAS 94-09-7; molecular formula C9H11NO2; molecular weight 165.19) is an ester-class local anesthetic, structurally the simplest member of the para-aminobenzoate family (the primary aminobenzoate ester directly esterified to ethanol, lacking the diethylamino-ethanol group of procaine). The simpler structure produces a lipophilic, water-poorly-soluble compound suitable only for topical mucous membrane anesthesia; the absence of the tertiary amine restricts utility for infiltration and regional anesthesia. Benzocaine is the principal active ingredient in over-the-counter throat lozenges (Cepacol), oral analgesic gels (Anbesol, Orajel), topical preparations for hemorrhoidal and minor wound use, and topical ENT and bronchoscopy preparation. Mechanism is voltage-gated sodium channel block in surface nerve fibers contacted topically. Onset is rapid (15 to 60 seconds on mucous membranes); duration is 5 to 15 minutes. The principal safety concern is dose-dependent methemoglobinemia, more pronounced than with prilocaine, that has driven FDA boxed warnings against benzocaine spray and gel use in infants and limited topical doses in children and adults. The mechanism is hepatic conversion of benzocaine to nitroso and N-hydroxy metabolites that oxidize hemoglobin iron to the ferric state. Clinical methemoglobinemia is reported with topical mucosal application of as little as 250 mg in vulnerable individuals; the risk is amplified in G6PD deficiency, infancy (low NADH-methemoglobin reductase activity), and concurrent oxidant drug exposure. Methylene blue is the rescue therapy. The FDA advised in 2018 against benzocaine teething gels in infants under 2 years.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Memantine, sold as Namenda, is an Alzheimer disease medication that blocks the NMDA glutamate receptor. Unlike most NMDA antagonists it has a brief, low-affinity profile that allows normal learning while preventing the chronic excitotoxicity associated with neurodegeneration. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Uncompetitive NMDA receptor antagonist with ancillary 5-HT3 antagonist and alpha-7 nicotinic receptor activity
A 3,5-dimethyladamantane derivative developed by Merz Pharmaceuticals as a moderate-affinity, voltage-dependent, uncompetitive NMDA receptor open-channel blocker approved for moderate-to-severe Alzheimer’s disease, distinguished from high-affinity NMDA antagonists by rapid off-rate kinetics that permit preservation of physiological synaptic transmission while attenuating tonic excitotoxic glutamatergic signaling.
Abstract
Memantine (1-amino-3,5-dimethyladamantane; CAS 19982-08-2; molecular formula C12H21N; molecular weight 179.30) is a moderate-affinity, uncompetitive, voltage-dependent, open-channel blocker of the N-methyl-D-aspartate (NMDA) subtype of the ionotropic glutamate receptor, approved in the European Union (2002) and the United States (2003) for the treatment of moderate-to-severe Alzheimer’s disease. The compound is an adamantane derivative structurally related to the antiviral agent amantadine, first synthesized and patented by Eli Lilly and Company in 1968 as a potential antidiabetic agent, subsequently identified as possessing central nervous system activity in the early 1970s by Merz Pharmaceuticals, and characterized as an NMDA receptor channel blocker by Bormann in 1989 [1]. The pharmacological distinction of memantine from high-affinity NMDA channel blockers such as phencyclidine, dizocilpine (MK-801), and ketamine rests on three properties: moderate binding affinity (IC50 approximately 1 micromolar at resting membrane potential), strong voltage dependence that ensures rapid unblocking upon physiological depolarization, and fast open-channel blocking and unblocking kinetics (time constant of unblock approximately 5 seconds) [2, 3]. These kinetic properties allow memantine to attenuate the tonic, pathologically elevated glutamatergic signaling associated with excitotoxic neurodegeneration while preserving the transient, high-amplitude synaptic NMDA receptor activation required for long-term potentiation and normal cognitive function. In addition to the primary NMDA receptor mechanism, memantine acts as a non-competitive antagonist of the serotonin 5-HT3 receptor at concentrations comparable to its NMDA receptor affinity (IC50 approximately 1 to 2 micromolar) [4] and as a non-competitive antagonist of the alpha-7 nicotinic acetylcholine receptor (IC50 approximately 0.34 to 5 micromolar depending on assay conditions) [5]. Weak agonist activity at the sigma-1 receptor (Ki approximately 2.6 micromolar) has been reported but is unlikely to contribute at therapeutic plasma concentrations [6]. Pharmacokinetics in humans are characterized by near-complete oral bioavailability (approximately 100 percent), a long plasma elimination half-life of 60 to 80 hours permitting once- or twice-daily dosing, minimal hepatic cytochrome P450-mediated metabolism, and predominantly renal elimination with approximately 48 percent of the administered dose excreted unchanged in urine through pH-dependent tubular reabsorption and active tubular secretion [7, 8]. The compound is well tolerated at the approved dose of 20 mg per day; the principal adverse events in registration trials were dizziness, headache, confusion, and constipation, occurring at rates comparable to or modestly exceeding placebo [9, 10]. Two pivotal registration trials established efficacy: the Reisberg et al. (2003) study in 252 patients with moderate-to-severe Alzheimer’s disease demonstrated significant benefit over placebo on the Severe Impairment Battery (SIB) and the Clinician’s Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) over 28 weeks [9], and the Tariot et al. (2004) study in 404 patients already receiving stable donepezil demonstrated that the addition of memantine produced significant improvement in cognitive, functional, behavioral, and global measures compared to placebo plus donepezil [10]. Memantine is marketed as Namenda (Forest Laboratories, now Allergan/AbbVie) in the United States, as Axura (Merz) and Ebixa (Lundbeck) in Europe, and under multiple generic names globally. An extended-release formulation (Namenda XR, 28 mg once daily) was approved in 2010, and a fixed-dose combination of memantine extended-release and donepezil (Namzaric, 28 mg/10 mg) was approved in 2014. This monograph reviews the chemistry, synthesis, and structural pharmacology of memantine; the multi-target receptor pharmacology with emphasis on the NMDA receptor mechanism; comprehensive human pharmacokinetics; preclinical neuroprotection and cognition pharmacology; the clinical evidence base across Alzheimer’s disease, vascular dementia, neuropathic pain, and investigational indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse events and safety signal; and a comparative assessment of five therapeutic alternatives against memantine on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
A defined oral peptide fraction prepared from porcine brain tissue, marketed as a nutraceutical analog of intravenous Cerebrolysin for cognitive support.
Abstract
N-PEP-12 is a porcine-brain-derived peptide preparation developed by Ever Neuro Pharma (the manufacturer of Cerebrolysin) as a defined orally bioavailable analog of the parent intravenous nootropic. Cerebrolysin itself is a complex hydrolysate of porcine cerebral cortex containing approximately 25 percent free amino acids and 75 percent low-molecular-weight peptides (less than 10 kDa) administered by daily intravenous or intramuscular injection in courses of 10 to 30 days for vascular dementia, Alzheimer’s disease, ischemic stroke recovery, and traumatic brain injury indications across approximately 50 jurisdictions (Europe, Asia, Russia, South America). The intravenous administration is operationally restrictive; N-PEP-12 was developed to provide a similar peptide profile in a daily oral capsule format suitable for outpatient and over-the-counter use. The published characterization describes a peptide molecular weight distribution of 1 to 10 kDa with similar amino acid composition to Cerebrolysin and shared neurotrophic activity in cortical neuron culture (BDNF and IGF-1 mimetic effects, neurite outgrowth, protection against amyloid-beta and glutamate excitotoxicity). Clinical evidence is more limited than for Cerebrolysin: published randomized trials in mild cognitive impairment (MCI) and age-associated memory impairment report modest cognitive improvements over 90 days in single-center studies. The compound is not FDA-approved; it is marketed as a dietary supplement in the United States and as a nutraceutical or medicinal food in European jurisdictions. The principal limitation on the strength of the evidence is the small number of independent clinical trials and the dominance of the manufacturer-sponsored published record. Reconstitution is not required; oral capsules contain approximately 60 mg of peptide blend.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
A 15-residue synthetic peptide modeled on the second fibronectin-like domain of neural cell adhesion molecule, an FGFR1 partial agonist with neuroprotective and pro-cognitive activity in rodent models.
Abstract
FGL (FG Loop peptide; Glu-Val-Tyr-Val-Val-Ala-Glu-Asn-Gln-Gln-Gly-Lys-Ser-Lys-Ala; sometimes called the FGL peptide or NCAM-derived FGFR agonist; molecular weight approximately 1622 Da) is a synthetic 15-residue peptide modeled on the second fibronectin type III repeat (FnIII) domain of neural cell adhesion molecule (NCAM), specifically the Phe-Gly loop responsible for fibroblast growth factor receptor 1 (FGFR1) interaction. NCAM is a transmembrane glycoprotein expressed at high levels in developing and adult nervous system tissue that mediates cell-cell adhesion through homophilic NCAM-NCAM binding and signals across the membrane through cis-binding to FGFR1. The FGL peptide was designed at the University of Copenhagen by Elisabeth Bock and Vladimir Berezin as a small-molecule mimetic of the NCAM-FGFR interaction, capable of activating FGFR1 signaling without the broad effects of full NCAM ectodomain or full-length FGF ligands. Reported activities include neurite outgrowth promotion in primary cortical and hippocampal neurons, protection against glutamate excitotoxicity, anxiolysis and pro-cognitive effects in rodent fear conditioning and Morris water maze paradigms, and recovery promotion in models of traumatic brain injury and stroke. Routes studied include subcutaneous, intraperitoneal, and intranasal administration. Plasma half-life is short (approximately 30 minutes); the central nervous system exposure after intranasal administration is substantially higher than after parenteral routes, owing to direct olfactory and trigeminal pathway transport. The compound advanced through ENKAM Pharmaceuticals (a University of Copenhagen spin-out) into early clinical development for Alzheimer’s disease and cognitive impairment in the late 2000s; clinical development has not produced a marketed agent. The principal limitation on the strength of the evidence is the dominance of the originating laboratory’s publications and the absence of independent replication of key behavioral findings.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
N-acetylated Selank derivatives with extended pharmacokinetics
N-terminal-acetylated and amidated variants of the heptapeptide anxiolytic Selank, designed to extend plasma and central nervous system exposure beyond the parent peptide.
Abstract
NA-Selank (N-acetyl-Thr-Lys-Pro-Arg-Pro-Gly-Pro) and NA-Selank Amidate (the same N-acetylated heptapeptide with C-terminal amidation, Pro-NH2) are N-terminal-modified derivatives of Selank, the seven-residue peptide anxiolytic developed at the Russian Academy of Sciences as an analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg). The parent Selank is registered as a medicine in the Russian Federation as an intranasal anxiolytic at 0.15 percent solution; the principal pharmacological signature is anxiolysis without sedation, modest pro-cognitive activity, and immunomodulation through tuftsin-receptor binding on monocytes and natural killer cells. Selank itself has a short plasma half-life of minutes and is administered intranasally to leverage direct olfactory and trigeminal transport to the central nervous system; the N-acetyl modification at the threonine N-terminus blocks the principal aminopeptidase cleavage site and extends plasma half-life by approximately 5-fold, while the C-terminal amidation in the Amidate variant similarly blocks carboxypeptidase cleavage at the proline C-terminus. The combined modifications produce a heptapeptide with substantially extended exposure suitable for parenteral administration with central nervous system effect. Mechanism includes BDNF transcriptional upregulation, GABAergic and serotonergic modulation, and tuftsin-receptor immunomodulation. Both NA-Selank and NA-Selank Amidate are research-grade peptides without regulatory approval; published characterization is principally in Russian-language journals and is dominated by the originating Institute of Molecular Genetics RAS research group. Investigators should treat the extended-PK variants as research tools for studying parenteral Selank pharmacology and should consider that the immune-modulatory profile may be more pronounced with extended exposure than with the brief intranasal pulse achieved by the parent.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Procaine is the original synthetic local anesthetic, synthesized in 1905 by Alfred Einhorn and marketed by Hoechst as Novocain. It was developed as a non-addictive cocaine substitute and dominated the field from 1905 through the 1950s before lidocaine and the amide class displaced it owing to faster onset, longer duration, and far fewer allergic reactions. The ester-class downside: hydrolysis by plasma cholinesterase produces para-aminobenzoic acid (PABA), the dominant allergen in the class. Plasma half-life of procaine itself is under one minute; clinical infiltration block lasts only 30 to 60 minutes. Modern use is essentially restricted to short-procedure infiltration in patients with documented amide allergy and to a few dental applications. Procaine penicillin (the depot antibiotic formulation) is the oldest application of procaine in pharmaceutical formulation and is the principal reason most clinicians have heard of it. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Ester local anesthetic (short-acting)
The original synthetic local anesthetic introduced in 1905 as Novocaine, displaced by amide agents but retaining historical and reference status.
Abstract
Procaine (2-(diethylamino)ethyl 4-aminobenzoate; CAS 59-46-1; molecular formula C13H20N2O2; molecular weight 236.31) is the original synthetic local anesthetic, synthesized by Alfred Einhorn at the University of Munich in 1905 and marketed by Hoechst as Novocain. The compound was developed as a cocaine substitute that lacked the abuse liability and addictive potential of the natural alkaloid; the ester linkage between the aromatic ring and the amino alcohol substantially reduces lipophilicity relative to cocaine while preserving sodium channel block. Procaine was the dominant local anesthetic from 1905 through approximately the 1950s, when lidocaine and the amide class displaced it owing to faster onset, longer duration, and substantially lower allergic reaction incidence. The principal limitation of procaine and the ester class is hydrolysis by plasma cholinesterase to para-aminobenzoic acid (PABA), the dominant allergen in the class and a substrate for hapten-mediated immune reactions in sensitized individuals. The plasma half-life is short (less than 1 minute through cholinesterase clearance); duration of clinical infiltration block is 30 to 60 minutes, much shorter than amide agents. Mechanism is voltage-gated sodium channel block with state-dependent kinetics; the lower lipid solubility relative to amide agents corresponds to slower onset and weaker block per milligram. Maximum recommended dose is 7 mg/kg, with adjustment for patients with cholinesterase deficiency (prolonged duration, increased systemic exposure). Modern clinical use is limited to short-procedure infiltration in patients with documented amide allergy and to several dental applications in markets where the ester formulations remain available. Procaine penicillin (combined with penicillin G as a depot) extends antibiotic plasma levels and is the oldest application of procaine in formulation.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Zonulin antagonist octapeptide and tight junction modulator
An eight-residue zonulin receptor antagonist developed by Innovate Biopharmaceuticals (now 9 Meters Biopharma) as the first specific gut tight junction modulator advanced to Phase 3 in celiac disease.
Abstract
Larazotide acetate (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly; CAS 258818-34-7; molecular weight 754.86 free peptide) is an eight-residue synthetic peptide developed at the University of Maryland by Alessio Fasano and colleagues as a competitive antagonist at the zonulin receptor. Zonulin (also designated pre-haptoglobin 2) is the human ortholog of the Vibrio cholerae zonula occludens toxin (ZOT) and is the only known endogenous regulator of intestinal epithelial tight junction permeability; activation of the zonulin pathway in response to gluten exposure or other triggers produces transient opening of intestinal tight junctions and translocation of luminal antigens into the lamina propria, contributing to celiac disease pathogenesis and a broader leaky-gut phenotype implicated in autoimmune and inflammatory conditions. Larazotide binds the zonulin receptor and blocks ZOT/zonulin-induced tight junction disassembly without directly affecting baseline tight junction integrity. The compound was advanced through Phase 1 and Phase 2 trials in celiac disease and entered Phase 3 (CeDLara) for the residual gluten-cross-contamination phenotype in patients on a gluten-free diet who continue to experience symptoms. The Phase 3 readout in 2022 did not meet the primary endpoint of celiac disease patient-reported outcome, and 9 Meters Biopharma announced discontinuation of the program. Despite the clinical setback in celiac disease, larazotide remains a pharmacologically distinct research tool for tight junction modulation in inflammatory bowel disease, multiple sclerosis, and other indications where intestinal barrier dysfunction is implicated. Oral bioavailability is essentially zero (the peptide acts in the gut lumen and is not absorbed); the route of administration is per oral as a sustained-release formulation. Adverse events in clinical trials were mild and dominated by gastrointestinal effects.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Pindolol is an old beta-blocker, FDA-approved in 1982, that lowers blood pressure by quieting the heart. What makes it interesting outside cardiology is a side activity: it binds tightly to a serotonin receptor (5-HT1A) that normally throttles serotonin release. By turning off that throttle alongside an SSRI antidepressant, pindolol was hypothesized to make the SSRI kick in faster (days rather than weeks). Trials produced mixed results, with some studies showing accelerated response in depression and others showing nothing. It is still used occasionally in psychiatry as an SSRI booster, but never became standard practice. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Non-selective beta-adrenergic antagonist with 5-HT1A partial agonism
A non-selective beta-blocker with intrinsic 5-HT1A partial agonism; investigated as an SSRI augmenting agent.
Abstract
Pindolol (1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; CAS 13523-86-9; molecular formula C14H20N2O2; molecular weight 248.32) is a non-selective beta-adrenergic antagonist with intrinsic sympathomimetic activity (partial agonism) and 5-HT1A partial agonism, approved by the FDA in 1982. The compound’s distinguishing pharmacological feature in psychiatric research is high-affinity 5-HT1A binding (Ki approximately 50 nM) with partial agonist activity at presynaptic autoreceptors; concurrent administration with an SSRI desensitizes the autoreceptor more rapidly than the SSRI alone, hypothetically accelerating the antidepressant response. Multiple placebo-controlled trials in the 1990s and 2000s reported faster onset (1 to 2 weeks shorter latency) but inconsistent overall efficacy improvement. Plasma half-life is 3 to 4 hours; metabolism is hepatic. Approved indications in cardiology include hypertension and angina; the SSRI augmentation use remains off-label. Used as the canonical 5-HT1A binding beta-blocker in mechanism studies.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Thymopentin is a 5-amino-acid synthetic peptide representing the active region of thymopoietin. Used historically for psoriasis and immune modulation. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Synthetic pentapeptide of thymopoietin
A synthetic pentapeptide fragment (residues 32-36) of thymopoietin marketed in Europe and Asia for immunomodulation in chronic infections and autoimmune disease.
Abstract
Thymopentin (Timunox, TP-5; Arg-Lys-Asp-Val-Tyr; CAS 69558-55-0; molecular weight 679.78) is a synthetic pentapeptide corresponding to residues 32-36 of thymopoietin, a thymic hormone. The fragment retains the immunomodulatory activity of full-length thymopoietin. The compound is approved in Italy and several Asian countries for primary immunodeficiency, hepatitis B, atopic dermatitis adjunct, and autoimmune disease support. Mechanism includes T-cell maturation, NK cell modulation, and cytokine balance effects. Administered subcutaneously. Doses are 50 mg three times weekly in clinical use.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
